Tag: CDK4/6 Inhibitor Abemaciclib

Home / CDK4/6 Inhibitor Abemaciclib

Categories

Abemaciclib with endocrine therapy is approved by FDA in HER 2 positive breast cancer

March 2023: Abemaciclib (Verzenio, Eli Lilly and Company) and endocrine therapy (tamoxifen or an aromatase inhibitor) have been approved by the Food and Drug Administration (FDA) for the adjuvant tre...
cdk4-6-inhibitor-abemaciclib

Scan the code